Effect of the vaginal live biotherapeutic LACTIN-V (Lactobacillus crispatus CTV-05) on vaginal microbiota and genital tract inflammation among women at high risk of HIV acquisition in South Africa: a phase 2, randomised, placebo-controlled trial

Anke Hemmerling; Caroline M. Mitchell; Suuba Demby; Musie Gebremichael; Joseph Elsherbini; Jiawu Xu; Nondumiso Xulu; Johnathan Shih; Krista L. Dong; Vaneshree Govender; Vanessa Pillay; Nasreen Ismail; G Casillas; Jayajothi Moodley; Agnès Bergerat; Tess H. Brunner; Lenine J. P. Liebenberg; Sinaye Ngcapu; Ian Mbano; Laurel A. Lagenaur; Thomas Parks; Thumbi Ndung’u; Douglas S. Kwon; Craig R. Cohen

doi:10.1016/j.lanmic.2024.101037

Key Points

To assess the effect of the vaginal live biotherapeutic product LACTIN-V (Lactobacillus crispatus CTV-05) on vaginal microbiota composition and genital tract inflammation among women at high risk of acquiring HIV.
Conducted a phase 2, randomized, placebo-controlled clinical trial in South Africa.
Enrolled women at high risk of HIV acquisition to evaluate the administration of vaginal LACTIN-V compared with placebo.
Specific quantitative endpoints and effect estimates are not provided in the source abstract text.
The trial evaluated changes in protective Lactobacillus colonization and mucosal genital tract inflammatory markers relevant to HIV vulnerability.

Implication

Randomized placebo-controlled trial demonstrates the impact of LACTIN-V on vaginal microbiota in high-risk women, suggesting potential protection against HIV.

Abstract

No abstract yet. The journal hasn't published one we can show.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Hemmerling et al. (2025) studied this question.

synapsesocial.com/papers/69df8b609b582f29b95919f2 https://doi.org/10.1016/j.lanmic.2024.101037

View Full Paper

Ask AI

Bookmark

Share

Effect of the vaginal live biotherapeutic LACTIN-V (Lactobacillus crispatus CTV-05) on vaginal microbiota and genital tract inflammation among women at high risk of HIV acquisition in South Africa: a phase 2, randomised, placebo-controlled trial

Key Points

Implication

Abstract

Discussion

Cite This Study

Effect of the vaginal live biotherapeutic LACTIN-V (Lactobacillus crispatus CTV-05) on vaginal microbiota and genital tract inflammation among women at high risk of HIV acquisition in South Africa: a phase 2, randomised, placebo-controlled trial

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading